• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Dendreon Corporation

Dendreon Corporation

  1. All
  2. 3rd Party
  1. Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results

    Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results

  2. Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

    Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGEĀ® (sipuleucel-T)

  3. Don't Bail on Biotech

    We see opportunity as fleeing investors trigger an irrational sell-off.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.